Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ConceptualCohortDefinition: T2DM-specific criteria - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "279346",
  "meta" : {
    "versionId" : "10",
    "lastUpdated" : "2024-11-16T19:33:24.954Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
    ]
  },
  "text" : {
    "status" : "empty",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Brian S. Alper"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
      "valueRelatedArtifact" : {
        "type" : "cite-as",
        "citation" : "CohortDefinition: T2DM-specific criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279346. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279346. Computable resource at: https://fevir.net/resources/Group/279346."
      }
    }
  ],
  "url" : "https://fevir.net/resources/Group/279346",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/279346",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "title" : "ConceptualCohortDefinition: T2DM-specific criteria",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening",
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership" : "conceptual",
  "combinationMethod" : "all-of",
  "characteristic" : [
    {
      "code" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "64572001",
            "display" : "Disease (disorder)"
          }
        ]
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "44054006",
            "display" : "Diabetes mellitus type 2 (disorder)"
          }
        ]
      },
      "exclude" : false,
      "description" : "Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria",
      "method" : [
        {
          "text" : "based on the World Health Organization (WHO) diagnostic criteria"
        }
      ]
    },
    {
      "code" : {
        "text" : "Medication exposure"
      },
      "valueCodeableConcept" : {
        "text" : "Daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs)\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"
      },
      "exclude" : false,
      "description" : "Have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine",
      "durationDuration" : {
        "value" : 1,
        "comparator" : ">=",
        "unit" : "years",
        "system" : "http://unitsofmeasure.org",
        "code" : "a"
      }
    },
    {
      "code" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "397669002",
            "display" : "Age"
          }
        ]
      },
      "valueRange" : {
        "low" : {
          "value" : 20,
          "unit" : "years",
          "system" : "http://unitsofmeasure.org",
          "code" : "a"
        },
        "high" : {
          "value" : 70,
          "unit" : "years",
          "system" : "http://unitsofmeasure.org",
          "code" : "a"
        }
      },
      "exclude" : false,
      "description" : "Are between 20 and 70 years old at the time of informed consent",
      "timing" : [
        {
          "contextCode" : {
            "coding" : [
              {
                "system" : "http://snomed.info/sct",
                "code" : "182771004",
                "display" : "Informed consent for procedure"
              }
            ]
          },
          "offsetDuration" : {
            "value" : 0
          }
        }
      ]
    },
    {
      "code" : {
        "coding" : [
          {
            "system" : "http://loinc.org",
            "code" : "39156-5",
            "display" : "Body mass index (BMI) [Ratio]"
          }
        ]
      },
      "valueRange" : {
        "low" : {
          "value" : 18.5,
          "unit" : "kilogram per square meter (kg/m2)",
          "system" : "http://unitsofmeasure.org",
          "code" : "kg/m2"
        },
        "high" : {
          "value" : 35,
          "unit" : "kilogram per square meter (kg/m2)",
          "system" : "http://unitsofmeasure.org",
          "code" : "kg/m2"
        }
      },
      "exclude" : false,
      "description" : "Have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening",
      "timing" : [
        {
          "contextCode" : {
            "text" : "screening"
          },
          "offsetDuration" : {
            "value" : 0
          }
        }
      ]
    }
  ]
}